• linkedin
  • Increase Font
  • Sharebar

    3 top concerns with IPF and comorbidities [SLIDESHOW]


    3 top concerns with ipf and comorbidities


    Patients with IPF should be carefully assessed for comorbidities, the most significant of which are cardiovascular disease (CVD) and lung cancer.

    “Both these comorbidities are associated with a significantly worse prognosis and are difficult to treat, with few established therapeutic options,” wrote Carlo Vancheri, professor with the Regional Centre for Rare Pulmonary Diseases, Department of Clinical and Experimental Medicine at the University of Catania, Italy, in a recent issue of Sarcoidosis Vasculitis and Diffuse Lung Diseases.

    Related: Physicians unsure about new IPF drugs

    Here are the major findings on IPF and comorbidities from Vancheri and his colleagues in Germany, France and Denmark:


    Christine Blank
    Contributing Editor Christine Blank is a freelance writer based in Florida.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available